INTRODUCTION
About 30% of all cancers, including lung adenocarcinoma (ADC), have an activating KRAS mutation, resulting in aberrant signaling through the mitogen-activated protein kinase (MAPK) pathway to promote tumor initiation and progression (1) (2) (3) (4) . KRAS mutant cancers respond poorly to conventional treatments, and no existing drug can effectively inhibit the range of oncogenic changes observed in the RAS protein (5-7). Thus, alternative therapeutic strategies have been developed, targeting downstream effectors of mutant Kirsten rat sarcoma (KRAS) through the use of MAPK kinase (MEK) inhibitors to block MAPK signaling (8, 9) . However, recent preclinical and clinical trials have demonstrated poor responses to MEK inhibitors due to the development of drug resistance (10) (11) (12) (13) .
Previous studies have demonstrated that resistance to MAPK disruption in lung cancer can occur because of an epithelial-tomesenchymal transition (EMT)-associated fibroblast growth factor receptor 1 (FGFR1) feedback reactivation of MAPK signaling (14) (15) (16) . Earlier work using the Kras LA1-G12D (Kras) and Kras LA1-G12D ;p53 R172H (KP) murine models demonstrated that EMT is epigenetically regulated by a double-negative feedback loop between the zinc finger E-box binding homeobox 1 (ZEB1) transcription factor and the miR-200 family of microRNAs (17) (18) (19) (20) (21) , whereby increased ZEB1 expression induces EMT and miR-200 expression reverts cells to an epithelial phenotype. In addition to therapy resistance and enhanced tumor progression, high ZEB1 expression in cancer cells results in metastatic disease, contributing to poor overall patient outcome (17, (22) (23) (24) (25) (26) (27) . Despite the importance of ZEB1 as a transcriptional repressor, pharmacologically targeting ZEB1 presents numerous challenges owing to its nuclear localization and pleiotropic effects. Thus, uncovering the contrasting sensitivities to specific targeted therapies between epithelial and mesenchymal tumor cells will facilitate the design of combinatorial treatment strategies in conjunction with MEK inhibitors. Our study identifies distinct subpopulations of lung cancer cells with differential MEK inhibitor sensitivities as defined by ZEB1 and interleukin-17 receptor D (IL17RD) expression, presenting potential markers associated with sensitivity to treatment. Therapeutically, suppression of ZEB1 through expression of miR-200 or histone deacetylase (HDAC) inhibition with mocetinostat sensitized resistant KRAS mutant lung cancers to MEK inhibitors, demonstrating a prospective combinatorial therapeutic strategy to overcome epigenetically mediated resistance across a broad range of KRAS mutant cancers.
approach with a barcoded, pooled small hairpin RNA (shRNA) library (28) targeting about 200 genes that have U.S. Food and Drug Administration (FDA)-approved pharmacological inhibitors (FDAome). The shRNA library was transduced into representative epithelial (393P) and mesenchymal (344P) murine lung cancer cell lines derived from the KP genetically engineered mouse model (GEMM) (17) and implanted subcutaneously in nude mice or cultured in vitro (Fig. 1A) . Tumors were harvested, shRNA barcodes were quantified by deep sequencing and referenced with the respective in vitro cell population, and the phenotypic impact of gene knockdown was inferred by the redundant shRNA activity (RSA) algorithm (29, 30) , where a lower rank of the shRNA barcodes signified dropout from the population and greater dependency on the gene for tumorigenesis (tables S1 and S2 in data file S1). Although both cell line models have activating Kras G12D and p53 mutations, comparison of the results revealed that epithelial 393P tumors were more reliant on MAPK genes for both in vitro and in vivo growth, whereas mesenchymal 344P tumor growth was independent of MAPK signaling (Fig. 1B, fig. S1A , and table S2).
Complementing the in vivo shRNA screen, we sought to elucidate the specific differences in protein signaling pathway rewiring between epithelial and mesenchymal lung cancer cells. Using reverse phase protein arrays (RPPAs) to analyze changes in cell signaling proteins in a high-throughput manner (31, 32) , we screened a panel of previously characterized (17, 22) isogenic murine and human epithelial lung cancer cell lines expressing ZEB1 or mesenchymal lung cancer cell lines expressing miR-200 and observed an increase in MAPK pathway signaling in cells with an epithelial phenotype (Fig. 1 , C and D, and tables S3 to S8 in data file S1).
Next, we translated the shRNA and RPPA findings by analysis of tumor samples from multiple cancer types in which RAS or rapidly accelerated fibrosarcoma (RAF) are commonly mutated to activate MAPK signaling, including lung ADC (30%), pancreatic (90%), colorectal (45%), and melanoma (70%) (4, 33) . Cross-platform correlation analyses of a previously derived EMT gene signature score (34, 35) or ZEB1 mRNA expression with MAPK signaling proteins as measured by RPPA from The Cancer Genome Atlas (TCGA) datasets showed a significant (P < 0.001) inverse correlation between EMT score and phosphorylated p90 ribosomal s6 kinase (p90RSK) in total lung and colorectal cancer patient samples (fig. S1B). Total melanoma samples did not show a statistically significant correlation between EMT score or ZEB1 and p90RSK, and no correlation between EMT and MAPK signaling was observed in total pancreatic cancer samples ( fig. S1B ). However, when patient samples across the four different tumor types were stratified for KRAS, NRAS, and BRAF mutations, there was an inverse correlation between EMT score and MAPK signaling (Fig. 1E  and fig. S1B ), although there was no significant correlation for KRAS mutant pancreatic cancer and NRAS/BRAF mutant melanoma ( fig. S1B) .
Validation of the bioinformatic datasets by Western blotting in a representative panel of RAS mutant human non-small cell lung cancer (NSCLC) cell lines showed higher activity of endogenous phosphorylated MAPK molecules MEK, ERK, and p90RSK in epithelial cell lines when stratified by the EMT markers ZEB1, E-cadherin, and vimentin and normalized to -actin expression (Fig. 1F) . In addition, suppression of ZEB1 through inducible miR-200 expression in mesenchymal cells increased MAPK signaling in a time-dependent manner, whereas induced ZEB1 expression in epithelial cells reduced MAPK signaling in a dynamic manner, at both the upstream and downstream components of the MAPK pathway (Fig. 1, G and H, and fig. S1 , C and D). To determine whether miR-200 activation of MAPK signaling was due to miR-200 repression of ZEB1, ZEB1 was knocked down in mesenchymal lung cancer cells, which similarly up-regulated MAPK pathway signaling ( fig. S1E ), confirming the importance of ZEB1 in regulating MAPK signaling. Overexpression of each individual miR-200 family member increased activated MAPK proteins, with miR-200c having the greatest effect, consistent with our previous work demonstrating that miR-200c binds most strongly to the ZEB1 3′ untranslated region ( fig. S1F) (35) .
Activation of MEK/ERK signaling in epithelial cells is driven by the RAS-RAF-MEK-ERK signaling cascade
Because MEK and ERK are activated by multiple signaling molecules, we next sought to establish the pathway responsible for differential MAPK activation. Analysis of the canonical RAS-RAF-MEK-ERK signaling cascade ( Fig. 2A) after reversion of the mesenchymal H157 and H1155 KRAS mutant cells to an epithelial state through induced, stable, or transient expression of miR-200 showed an increase in KRAS binding to the RAS binding domain (RBD) of RAF1 (CRAF), followed by activation of MAPK signaling ( Fig. 2B and fig. S2 , A and B). We observed that MAPK signaling is activated by miR-200 regardless of the driver mutation present, as miR-200 expression activated MAPK signaling in EGFR mutant (HCC827), NRAS mutant (H1299), EGFR/ RAS wild-type (WT) (H2882), and murine 344SQ KP lung cancer cells (Fig. 2C and fig. S2 , C and D). Consistent with our TCGA dataset correlation analyses, MAPK activation in epithelial cancer cells was not restricted to lung cancer cells, since pancreatic and colorectal cancer cell lines showed higher basal MAPK signaling activity in epithelial cells compared to mesenchymal cells, which was increased upon miR-200 expression (Fig. 2D) . Moreover, miR-200 expression upregulated MAPK signaling in epithelial, nontransformed BEAS2B cells at baseline or with constitutive expression of mutant KRAS G12D or EGFR 722-726 (36) (Fig. 2E ), demonstrating that this process is independent of oncogenic and comutational events.
To verify that the RAS-RAF-MEK pathway is necessary to activate p-ERK, we transiently knocked down KRAS by shRNA after miR-200 induction in the mesenchymal H157 model and observed a reduction in the miR-200-dependent MAPK signaling (Fig. 2F ). In addition, KRAS knockdown caused activation of cleaved caspase-3, indicating that cell survival is still dependent on KRAS despite the suppression of downstream MAPK signaling by ZEB1. Similarly, chemical inhibition of pan-RAF enzymatic activity and small interfering RNA (siRNA) knockdown of RAF isoforms individually or in combination demonstrated that MAPK activation was predominantly dependent on the enzymatic function of the CRAF isoform (Fig. 2, G and H) . Knockdown of all three RAF isoforms together produced the best suppression of p-MEK/p-ERK in miR-200-expressing cells, suggesting that miR-200-dependent MAPK signaling acts through RAF heterodimerization (Fig. 2H) .
In addition to the RAS-RAF pathway, we also examined the alternative focal adhesion kinase (FAK)/Ras-related C3 botulinum toxin substrate/p21-activated kinase (PAK) signaling pathway for differential regulation of p-MEK/p-ERK activation ( fig. S2E ). Stable or induced miR-200 expression in H157 cells decreased p-FAK, consistent with our previous work (25) , but increased p-PAK2 ( fig. S2 , F to I). The MEK (S298) phosphorylation site downstream of PAK1/2 also increased in a time-dependent manner but at a slower rate than MEK (S221/222) ( fig. S2G ). Small-molecule inhibition of FAK had no effect on MAPK signaling, whereas siRNA-mediated knockdown of PAK1 and/or PAK2 showed only partial contribution of PAK2 in activating MAPK signaling but to a much lower degree than RAS-RAF ( fig. S2, H and I ). Together, these data suggest that the miR-200-dependent increase in MAPK signaling is dependent on the RAS-RAF-MEK-ERK pathway, rather than activation of a bypass signaling mechanism.
Regulation of MAPK pathway signaling is linked to ZEB1 by differential expression of the scaffold protein IL17RD We next sought to ascertain the mechanism of MAPK activation in epithelial cells with high miR-200 expression versus suppression of signaling in mesenchymal cells with low miR-200 and high ZEB1 expression. To determine whether signaling was due to upstream growth factor stimulation of receptor tyrosine kinases (RTKs) or other mitogen-activated receptors, the KRAS mutant H157 cells with or without miR-200 expression were cultured in serum-free medium for 24 hours and then stimulated with either fetal bovine serum (FBS)-containing medium or epithelial growth factor (EGF) for 4 hours. In the mesenchymal control cells, there was a marked reduction in MAPK signaling under serum-free conditions compared to FBS stimulation, and EGF only marginally activated signaling (Fig. 3A) . However, cells with miR-200 induction continued to have increased MAPK signaling regardless of culture conditions (Fig. 3A) , suggesting that miR-200-dependent activation of the MAPK pathway in KRAS mutant cells occurs through an intracellular mechanism, independent of extrinsic factors.
Because miR-200-mediated activation of MEK/ERK signaling occurs predominantly through the RAS-RAF signaling junction, is dependent on multiple RAF isoforms, and is intracellularly regulated, our data implied that regulation of MAPK by ZEB1 depends on changes in inhibitory or scaffolding proteins. We performed quantitative polymerase chain reaction (qPCR) analysis for expression of MAPK inhibitory and scaffold genes reported to interact with RAF (37), with and without miR-200 induction ( Fig. 3B and fig. S3 , A to C). Inhibitory genes with at least 50% decrease or scaffold genes with at least twofold increase in expression after miR-200 induction were selected for further analysis ( Fig. 3B and fig. S3C ) identified kinase suppressor of ras 2 (KSR2), stratifin (SFN/14-3-3), connector enhancer of kinase suppressor of ras 2 (CNK2), soc-2 suppressor of clear homolog (SHOC2), and IL17RD as potential targets that were significantly (P < 0.01) up-regulated at least twofold upon miR-200 expression (Fig. 3B ). Western blot validation of the qPCR data showed no observable differences in SHOC2 or CNK2 protein expression ( fig. S3F ). Although miR-200 expression increased 14-3-3 protein and KSR2 mRNA, knockdown of either gene after miR-200 induction had no effect on MAPK signaling (fig. S3, G and H).
We next focused our analysis on the regulatory role of IL17RD on MAPK signaling. Correlation analysis of IL17RD mRNA expression to our previously reported 76-gene EMT signature score (34) in a panel of 77 human lung cancer cell lines showed a statistically significant (P = 0.0075) inverse correlation between IL17RD and EMT signature (Fig. 3C) . Validation of the correlation analysis and IL17RD qPCR data by Western blotting in a panel of epithelial and mesenchymal RAS mutant human lung, pancreatic, and colorectal cancer cell lines confirmed higher basal IL17RD expression in epithelial cells compared to mesenchymal cells ( Fig. 3D and fig. S3I ), with induction of IL17RD upon miR-200 expression in multiple models and suppression of IL17RD after ZEB1 expression in epithelial H441 cells ( Fig. 3E and fig. S3 , I and J). Knockdown of IL17RD by shRNA in miR-200-expressing H157 cells reduced MAPK signaling (Fig. 3F) , whereas overexpression of IL17RD in mesenchymal H157 and A549 cells increased MAPK signaling (Fig. 3 , G and H). Although IL17RD was initially implicated in inhibiting fibroblast growth factor (FGF)-induced MAPK signaling (43) , in FGF-independent contexts, IL17RD has been shown to promote MAPK signaling (44, 45) . Consistent with these reports, analysis of FGFR1 protein revealed a reciprocal expression to IL17RD, where mesenchymal cells had greater expression of FGFR1 compared to epithelial cells (fig. S3, I and K) and transient IL17RD overexpression caused a decrease in FGFR1 protein ( fig. S3L ).
Considering the negative correlation between IL17RD and EMT, we next sought to define the regulatory mechanism of IL17RD gene expression by ZEB1 or miR-200. Analysis of the human IL17RD promoter region using the JASPAR transcription factor database (http://jaspar.genereg.net/) predicted multiple potential ZEB1 E-box recognition sites (Fig. 3I ) responsible for transcriptional repression (21, 22, 46, 47) . ZEB1 ChIP qPCR assays of the endogenous IL17RD promoter in mesenchymal H157 cells with or without miR-200 expression confirmed direct binding of ZEB1 to the IL17RD promoter, with the highest signal occurring 190 and 680 base pairs upstream of the IL17RD transcriptional start site (Fig. 3J ). Luciferase reporter assays with the WT IL17RD promoter region confirmed transcriptional repression by ZEB1, which was abrogated by introduction of mutations into the two main ZEB1 binding sites (as assessed by ChIP) individually and in combination (Fig. 3K ).
Mesenchymal lung cancer cells and tumors are resistant to MEK inhibition
To functionally validate our shRNA screen and mechanistic findings, we treated a panel of human and murine KRAS mutant lung cancer cell lines, stratified as either epithelial or mesenchymal based on previous profiling (17, 22, 24) , with MEK inhibitors. Although we did not observe a significant difference in baseline proliferation rate between epithelial and mesenchymal murine lung cancer cells ( fig. S4A ), mesenchymal cells were more resistant to both of the MEK inhibitors selumetinib (AZD6244) and trametinib ( To validate our in vitro findings in an in vivo context, we first analyzed primary syngeneic tumors generated by implantation of epithelial 393P and mesenchymal 344SQ murine lung cancer cells in syngeneic WT mice (17) . Immunohistochemical (IHC) staining of tumor tissues for IL17RD, p-ERK, and the EMT markers (nuclear ZEB1, membranous E-cadherin, and vimentin) showed that low ZEB1 and vimentin staining were associated with high IL17RD, p-ERK, and membrane-localized E-cadherin signals, whereas high ZEB1 and vimentin expression were associated with an opposing pattern (Fig. 4C) . Consistent with these findings, in vivo administration of the MEK inhibitor selumetinib (AZD6244) significantly (P < 0.01) reduced tumor growth only in epithelial 393P tumors, whereas mesenchymal 344SQ tumors were highly resistant to treatment (Fig. 4D and table S9 in data file S1). However, despite the pronounced efficacy, 80% of 393P tumors eventually developed resistance to MEK inhibition, reaching sizes comparable to those of control tumors by 12 weeks, and developed a higher number of metastatic lung lesions compared to untreated control or drug-sensitive tumors (Fig. 4D) . IHC analysis of the vehicle control (393P vehicle) and AZD6244-sensitive (393P AZD6244) tumors after 7 weeks, and the AZD6244-resistant (393P AZD-R) primary tumors after 12 weeks confirmed the efficacy of AZD6244 in suppressing p-ERK and revealed that the resistant tumors had undergone EMT (displaying high nuclear ZEB1, low E-cadherin, and high vimentin expression compared to control tissues) and lacked expression of IL17RD (Fig. 4E) . We also observed increased vimentin even in AZD6244-sensitive 393P tumors (393P AZD6244) after MEK inhibition. In addition to IHC stains of the tumor tissue, cell lines were generated from 393P vehicle control and AZD6244-resistant tumors (393P AZD-R), and Western blot analyses confirmed the tumor IHC stains (fig. S4E ). Fig. 5A and fig. S4F ). Conversely, induced ZEB1 expression in epithelial cells increased resistance to MEK inhibitor treatments (Fig. 5B  and fig. S4G ). Because increased MAPK signaling in epithelial cells is mechanistically dependent on IL17RD, we constitutively expressed IL17RD in human and murine mesenchymal cells and found that it was sufficient to sensitize the resistant lines to MEK inhibitor (Fig. 5C) .
IL17RD is sufficient to sensitize mesenchymal lung tumors to MEK inhibition
To validate our findings in an in vivo context, we first induced miR-200 expression in 344SQ syngeneic tumors and treated them with AZD6244. Although miR-200 increased p-ERK in the tumors ( fig. S5A ), miR-200 expression alone was sufficient to decrease tumor growth, and combination with AZD6244 treatment had an additive effect that reduced average tumor size by more than 90% (Fig. 5D and table S10 in data file S1), similar to the treatment response of epithelial 393P tumors that have high basal expression of miR-200 (Fig. 4D) . Constitutive expression of IL17RD in 344SQ cells and tumors increased MAPK signaling with no effect on ZEB1 ( fig. S5 , B and C), moderately decreased tumor volume, and resensitized the tumors to AZD6244 treatment, although not to the same degree as induced miR-200 expression (Fig. 5E and table S11 in data file S1). Although IL17RD expression alone did not significantly suppress metastases, combination of IL17RD expression with MEK inhibition reduced lung metastatic lesions (Fig. 5E) . Knockdown of IL17RD in epithelial 393P cells reduced MAPK signaling with no change in ZEB1 expression ( fig. S5, D and E) , reduced in vitro cell growth rate as measured by colorimetric absorption over time ( fig. S5F) , and further sensitized 393P cells to in vitro MEK inhibition ( fig. S5G) . Knockdown of IL17RD in 393P tumors significantly (P < 0.01) reduced in vivo tumor growth to a similar degree as MEK inhibition alone ( Fig. 5F and table S12 in data file S1), emphasizing the dependency on the scaffold protein for MAPK signaling and tumor growth. Combination of IL17RD knockdown and MEK inhibitor had a slight additive effect on reducing tumor growth overall, and two of the tumor samples regressed completely in the combination treatment group (Fig. 5F ). ) mice, generated through intratracheal administration of adenovirus expressing Cre recombinase (48) . Histological analyses demonstrated that KP −/+ and KP −/− mice (4 to 6 months after induction) displayed multiple tumor regions that stained positively for thyroid transcription factor 1 (TTF1) and displayed high ZEB1 expression compared to Kras G12D mice (Fig. 6A  and fig. S6 ). Similar to our observations in syngeneic primary tumors (Fig. 4C ), tumor regions with high ZEB1 expression had low amounts of IL17RD and p-ERK, whereas tumor regions with low ZEB1 expression had high IL17RD and p-ERK (Fig. 6A and fig. S6 ).
ZEB1 expression in lung tumors
To assess whether our findings in the KP mice were due to ZEB1 expression driven by diminished miR-200 expression rather than a secondary effect of p53 loss, we generated a mouse model with condi- (Fig. 6A and fig. S6 ). We also observed tumor heterogeneity in heterozygous KM −/+ mice similar to that of the KP −/+ mice, with certain tumor regions displaying low ZEB1 expression with high IL17RD and p-ERK ( fig. S6 ). However, homozygous KM −/− lung tumors displayed fewer regions of heterogeneity than heterozygous mice. IHC stains for TTF1 in tumor tissues from the various Kras mutant models demonstrated that, at 4 to 6 months after induction, all lung tumor tissues were pathologically well differentiated (Fig. 6A ) and confirmed that tumor regions in KM mice were of lung origin.
We next assessed the sensitivity of our murine lung cancer models to therapeutic MEK inhibition. Three months after induction of lung tumors in Kras G12D , KP, and KM animals by adeno-Cre, tumor
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formation was confirmed by micro-CT scans, and daily doses of single-agent AZD6244 were administered. Micro-CT image analysis of changes in overall lung tumor area and H&E lung tissue sections demonstrated that mice with the single Kras G12D mutation, which presented with low ZEB1 and high p-ERK, were sensitive to MEK inhibition, whereas KP and KM lung tumors were more resistant over 4 weeks of treatment (Fig. 6, B and C, fig. S8 , A and B, and table S13 in data file S1). We also observed that MEK inhibitor response in the KP and KM mice was dependent on zygosity, because none of the homozygous KP and KM mice showed reduction in tumor size after treatment. Because of the heterogeneous nature of the KP −/+ and KM −/+ mice, we analyzed the lung tumor tissues from the heterozygous mice after MEK inhibitor treatment and observed that the residual TTF1-positive tumor tissues expressed high amounts of ZEB1 and vimentin, with low expression of IL17RD, p-ERK, and E-cadherin ( fig. S8C) , showing a similar pattern to the syngeneic 393P AZD-R tumors (Fig. 4E) . Overall, these data demonstrate that ZEB1 expression inversely correlates with IL17RD expression and MAPK signaling in autochthonous Kras mutant lung cancers, resulting in in vivo resistance to MEK inhibitors.
Mocetinostat suppresses ZEB1 function, derepresses IL17RD expression, and sensitizes resistant tumor cells to MEK inhibition
Identifying combinatorial treatment strategies with MEK inhibitors to reduce tumor growth and progression is vital for improving patient survival in KRAS mutant lung cancer. Previous studies have shown that the class I HDAC inhibitor mocetinostat reverts the EMT phenotype through restoring the expression of epithelial microRNAs, including the miR-200 family (51) . Treatment of mesenchymal H157 cells with mocetinostat induced miR-200 expression and caused the cells to adopt a more epithelial phenotype at the molecular level, resulting in increased IL17RD expression, increased MAPK signaling, and decreased FGFR1 (Fig. 7, A to C, and fig. S9A ). To verify that the observed changes were independent of secondary effects due to histone acetylation, H157 cells were treated with the pan-HDAC inhibitor trichostatin A and showed no observable changes in either EMT markers or MAPK signaling molecules ( fig. S9B ). Mocetinostat treatment of syngeneic 344SQ tumors produced an increase in IL17RD and p-ERK by IHC analysis, concomitant with an increase in E-cadherin localization to the cell membrane (Fig. 7D) . Although we did not observe changes in ZEB1 or vimentin expression by IHC after mocetinostat treatment ( fig. S9C ), qPCR analysis of the mocetinostat-treated 344SQ tumors showed an up-regulation of both miR-200c and Il17rd, demonstrating functional suppression of ZEB1 activity (Fig. 7E) . As previously reported, these findings suggest that, in addition to direct promoter binding, ZEB1 can functionally repress expression of epithelial-associated genes through recruitment of HDACs (51) (52) (53) (54) (55) .
Because epithelial cancer cells with low ZEB1 are sensitive to MEK inhibition, suppression of ZEB1 in mesenchymal human and murine lung cancer cells in vitro with mocetinostat increased sensitivity to selumetinib treatment ( fig. S9D) . In vivo combinatorial administration of mocetinostat and selumetinib in mice bearing syngeneic 344SQ mesenchymal tumors had an additive effect on reducing average tumor size compared to single-agent AZD6244 treatment (Fig. 7F and table S14 in data file S1). Mocetinostat alone reduced tumor growth rate, with no observed decrease in the number and size of lung metastatic nodules. However, lung metastatic nodules were reduced in both number and size with dual HDAC and MEK inhibition (Fig. 7F) . To test the therapeutic effect on heterogeneous autochthonous tumors that more accurately mimic the p53 mutational status observed in patients with lung cancer, we treated the spontaneous KP mice between 7 and 8 months of age with AZD6244 alone or in combination with mocetinostat. Comparable with the adeno-Cre conditional lung tumor mouse models, lung tumors in Kras animals had low expression of ZEB1, correlating with high p-ERK ( fig. S9E ). Similarly, KP mice exhibited heterogeneity, with most of tumor regions expressing high expression of ZEB1, correlating with low phosphorylation of ERK, but a few regions had low ZEB1 and high p-ERK (fig. S9E) . Consistent with the adeno-Cre-inducible Kras mice, singlemutant Kras mice were responsive to MEK inhibition, whereas KP tumors were resistant (Fig. 7G and table S15 in data file S1). However, micro-CT image analysis demonstrated that combinatorial treatment with mocetinostat and AZD6244 reduced overall tumor area in KP but was unable to reverse drug resistance in the KM mice (Fig. 7 , G and H, and table S15), suggesting that mocetinostat induction of miR-200 is necessary to promote MEK inhibitor sensitivity. Our results present a promising combinatorial therapy with MEK inhibitors to treat KRAS mutant lung cancers.
Patients with poorly differentiated lung ADCs display high ZEB1 expression and lower phosphorylation of ERK Last, to further evaluate the clinical context of our findings beyond TCGA analyses, we determined the correlation between p-ERK, IL17RD, and ZEB1 expression in human lung cancer patient samples. Pathological assessment of cytoplasmic and nuclear p-ERK H scores by IHC staining (Fig. 8A ) in a cohort of patient lung tumor tissues (n = 451) showed higher expression of p-ERK in patients with lung ADC versus patients with squamous cell carcinoma (SCC) (fig. S10, A and B), consistent with the frequent activation of this pathway in ADC histology. However, pathological analyses revealed that poorly differentiated ADC tumors have lower amounts of nuclear p-ERK when compared to moderately differentiated ADC tumors (Fig. 8B) . Cytoplasmic p-ERK showed no statistically significant changes between differentiation grades ( fig. S10C) .
Because ZEB1 is important in regulating MAPK signaling, we next wanted to determine the correlation between ZEB1 and p-ERK expression in patients with lung tumor. Using data from ZEB1 IHC stains performed in a previous study (24) , we compared H score values of ZEB1 and p-ERK (Fig. 8A) in each patient tumor sample and observed a significant (P = 0.0003) negative correlation between ZEB1 and nuclear/cytoplasmic p-ERK in ADC histologic subtypes but not in SCC samples (Fig. 8B and fig. S10, D to F) . Analysis of ZEB1 H score and p-MEK did not show any significant correlation in patient tumor samples ( fig. S10, G to I) . Because of the lack of optimized IL17RD antibodies that produced IHC stains of clinically acceptable quality for scoring, we analyzed gene expression profiles in patient lung tumor samples from the PROSPECT dataset and observed a significant (P = 0.00567) inverse correlation between IL17RD and ZEB1 mRNA levels (Fig. 8C) . However, IL17RD expression was not independently prognostic of overall patient survival in this dataset ( fig. S10J ). Collectively, our data support a model in which suppression of ZEB1 function in lung cancers promotes MAPK signaling and dependency through up-regulation of IL17RD, thereby sensitizing KRAS mutant lung cancers to MEK inhibition (Fig. 8D) .
DISCUSSION
The poor response to conventional chemotherapy or MEK inhibitor therapy in patients with KRAS mutant cancers emphasizes the need to identify the underlying resistance mechanisms, build appropriate biomarkers for patient selection, and develop rational combinatorial treatment strategies (12, 13) . Tumor heterogeneity and the emergence of resistant subpopulations are likely explanations accounting for some of the observed resistance. By carrying out the in vivo FDAome shRNA dropout screen in conjunction with proteomic profiling, we not only identified differential MAPK signaling activation and dependency during a ZEB1-regulated EMT but also of IL17RD alone activated MAPK signaling, sensitized ZEB1-high tumors to MEK inhibition, and reduced lung metastasis, whereas IL17RD knockdown in ZEB1-low tumors reduced tumor growth to the same degree as MEK inhibitor monotherapy. Considering that stable manipulation of IL17RD did not alter ZEB1 expression or produce feedback regulation of MAPK signaling, our data suggest that increased ZEB1 expression is still necessary to promote MAPKindependent tumor growth after IL17RD suppression. Our finding that IL17RD drives MAPK signaling in epithelial tumors presents a unifying mechanism along with the FGFR1 feedback model of resistance (15, 16) . Not only IL17RD has a reciprocal expression to FGFR1 and ZEB1 but also the scaffold protein negatively regulates FGFR1-asociated feedback activation of MAPK signaling (43, 45, 56) . Because of its correlation with MAPK signaling and inverse correlation with ZEB1 in murine models and human patient datasets, IL17RD may serve as an additional marker to predict MEK inhibitor sensitivity. However, the optimization of IL17RD detection antibodies for pathological purposes will be critical to further assess its role in predicting patient response to clinical MEK inhibitors. Because IL17RD is involved during development (43, 56) , is a negative regulator of EMT (57, 58) , and causes metastasis to become predominantly dependent on MAPK signaling, the broader role of IL17RD in counter-regulation and restructuring of global cell signaling patterns warrants future studies. Last, in addition to ZEB1 regulating IL17RD-mediated MAPK signaling, validation of our RPPA data revealed a continuous decrease in p90RSK with ZEB1 expression, which did not follow the same pattern as upstream MAPK signaling molecules. This correlation suggests another potential mode of ZEB1 regulation of MAPK signaling at the most downstream component of the MAPK pathway, consistent with the observed correlation between p90RSK and EMT in the TCGA datasets.
Because our results demonstrate an epigenetic basis for the rewiring of signal transduction pathways in the tumor cell subpopulations with high ZEB1 expression, consistent with findings from earlier studies (24, 25, 34, 59) , the application of combinatorial treatments is necessary to effectively prevent the outgrowth of resistant subpopulations. Separate studies have proposed a combination of MEK inhibitors with RTK-or FGFR1-specific inhibitors to reduce primary tumor growth (15, 16) . However, our in vivo shRNA screen suggests that the emergent MEK inhibitor-resistant population is in a ZEB1-high, MAPK-independent state, which drives tumor cell invasion and metastasis (17, (22) (23) (24) (25) (26) 35) , major causes of deaths of patients with lung cancer (27, 60) . In light of these data, we advocate an alternative combination based on the effects of the class I HDAC inhibitor mocetinostat to suppress the epigenetic function of ZEB1 and recapitulate the functional and molecular changes observed with forced miR-200 expression. We demonstrate that the combination of selumetinib with mocetinostat, currently undergoing testing in clinical trials (https:// clinicaltrials.gov/ct2/results?term=mocetinostat), not only decreases primary tumor growth in the syngeneic and various autochthonous models but also reduces metastatic disease as well, providing preclinical rationale for a combinatorial treatment strategy in patients.
Extending our findings to preclinical murine models to more accurately model tumor heterogeneity, we used our syngeneic KP tumor models, multiple previously characterized Kras mutant mouse models of lung cancer, and our conditional Kras In addition, important for translational therapeutic development, the combined RPPA and shRNA library screen data provide numerous additional drug targets that warrant further investigation to optimize combination strategies. A major advantage of applying the shRNA library screen to immunocompetent syngeneic models is the capability to detect target genes that may synergize with or antagonize immunotherapies. These combined high-throughput analyses will need to be further complemented with in vivo studies delineating changes in the tumor immune microenvironment as part of the systematic characterization of tumor progression and drug resistance.
Last, the ability to predict sensitivity to MEK inhibition based on ZEB1 status will allow for the establishment of other drug combinations-in addition to our proposed strategy-that target the resistant cancer cell subpopulations. Extending our preclinical therapeutic strategies to different RAS mutant cancer types, such as pancreatic and colorectal, may further improve the treatment options for patients with cancer. These results emphasize the importance of epigenetic changes and the need for biomarkers beyond the standard DNA mutation profiling to select patients who will likely benefit from single-agent therapy versus combinations.
MATERIALS AND METHODS

Study design
The objective of the study was to understand the mechanisms of MEK inhibitor resistance in KRAS mutant lung cancers and identify therapeutic targets in the resistant cell population. We used an in vivo shRNA screen in epithelial or mesenchymal murine lung cancer cell lines, targeting genes with FDA-approved compounds. Concurrently, we performed an RPPA proteomic profile on murine and human epithelial and mesenchymal lung cancer cell lines with manipulated miR-200 and ZEB1 expression. These initial analyses revealed enhanced MAPK signaling activity and dependency in epithelial lung cancer cells and tumors. Western blots and qPCR analyses verified our in vivo screen and RPPA profile and mechanistically identified IL17RD as the scaffold protein responsible for enhanced MAPK signaling in epithelial lung cancer cells. Luciferase reporter assays and ChIP were performed in technical and biological triplicates to verify direct ZEB1 suppression of IL17RD transcriptional activity.
Translating our findings therapeutically, human and murine epithelial and mesenchymal lung cancer cells were treated in vitro with the MEK inhibitors selumetinib and trametinib in experimental triplicates.
Findings from our mechanistic studies were validated in vivo by performing IHC analysis on multiple Kras mutant mouse models of lung tumors (n = 6 to 10). To therapeutically validate our findings in vivo, we treated syngeneic epithelial and mesenchymal murine lung tumors and multiple Kras GEMMs with selumetinib (n = 5 to 10 per group) unblinded in age-matched mice. We demonstrated that IL17RD was necessary to sensitize resistant tumors to MEK inhibition by overexpressing and knocking down IL17RD in mesenchymal and epithelial mouse lung tumors, respectively, and treated age-matched mice unblinded with selumetinib (n = 4 to 5 mice per group). To determine whether reversal of a ZEB1-driven EMT sensitized resistant lung cancers to MEK inhibition, syngeneic tumors and multiple KRAS GEMMs were treated unblinded with the class I HDAC inhibitor mocetinostat in combination with selumetinib (n = 5 to 8 mice per group). The numbers of mice were selected on the basis of resource availability and previous analyses to obtain statistical power with a minimum number of mice. End points of in vivo experiments were determined when veterinary technicians flagged mice for euthanasia based on primary tumor volume of >1.5 cm 3 . Data points from in vivo experiments were excluded if the animal died before the completion of the experiment or if the tumor regressed inexplicably.
Human lung tumor specimens were analyzed for markers by IHC, and H scores were assessed by unblinded two pathologists. For nuclear and cytoplasmic IHC, the percentage of staining intensity was scored as 0 (no staining), 1+ (weak staining), 2+ (moderate staining), and 3+ (strong staining), and the extension of the expression for each sample was reported as the percentage of positive cells. The final score (H score) was obtained by multiplying the intensity and reactivity extension values (range, 0 to 300). Human lung tumor tissue numbers were based on availability of samples, and all patient identities remained confidential.
Statistics
For analysis of RPPA data, a linear mixed model was applied to compare protein expression on a protein-by-protein basis between epithelial and mesenchymal groups; the model includes cell line effects as a random effect factor. The resulting P values were modeled by a beta-uniform model. To identify protein markers differentially regulated in epithelial and mesenchymal phenotypes, we used a false discovery rate of 0.05 as the cutoff. The Pearson correlation was used for distance matrix calculation, and Ward method was applied as linkage rule for the hierarchical clustering. Spearman's rank correlation was used to correlate gene expression and IHC H score values in human patient samples. Kaplan-Meier analysis was assessed by log-rank test. Statistical significance for all other experiments were assessed using two-tailed student's t test, and statistical significance was accepted as having a P value of less than 0.05.
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